CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 138 enrolled
Drug / intervention
Methamphetamine +1 moredrug
Likely dose
Methamphetamine 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04642820
NCT04642820Early Ph 1Completed
CompareCT.gov

Drugs Brain and Behavior

University of Chicago·interventional·Posted Nov 24, 2020·Updated Jan 9, 2025

In Brief

A Early Phase 1 clinical trial evaluating Methamphetamine and placebo oral tablet for Stimulant Use. Completed, enrolled 138 participants across 1 site.

Detailed Summary

In this project, we will examine individual differences in the effects of a stimulant drug, methamphetamine (MA), on mesolimbic reward function using fMRI.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStimulant Use
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Early Ph 1CompletedFinished
202120222023202420252026
First PostedNov 24, 2020
Enrollment StartNov 1, 2020
Primary CompletionOct 1, 2023
Study CompletionJun 1, 2024
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.6 years ago

Interventions

Methamphetaminedrug

Participants will be given 20 mg of Methamphetamine.

placebo oral tabletdrug

Participants will be given a placebo capsule that will only contain lactose.